COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

COMy 2026 | Professor Steven P. Treon: The Precision Era of Waldenström Macroglobulinemia—Overcoming Resistance and Exploring New Therapeutic Targets

From May 13–19, 2026, the 12th World Congress on Multiple Myeloma (COMy 2026) was held in Paris, France. As one of the most influential international meetings in the field of multiple myeloma and related plasma cell disorders, the congress brought together leading experts worldwide to discuss the latest advances in translational research, novel therapeutics, and patient care.
Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

Learning from History: Dr. Ludovico Docimo on the Rise of Robotic Surgery in Colorectal ORs

From May 15 to 17, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou. Dr. Ludovico Docimo, Professore Ordinario e Primario of the UOC of General, Minimally Invasive and Obesity Surgery at the University of Campania "Luigi Vanvitelli" (Italy), shared his view that robotic surgery will transform colorectal operating rooms, much like laparoscopy did.
From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

From Screening to Precision MDT: Prof. Zhang Suzhan on the “China Solution” for Colorectal Cancer

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was convened in Hangzhou, Zhejiang Province. Prof. Zhang Suzhan from the Second Affiliated Hospital, Zhejiang University School of Medicine attended the meeting and shared his insights on colorectal cancer screening, precision MDT management, and localized Chinese clinical solutions.
Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Sino-French Breast Reconstruction Congress | Professor Fan Li: From “One-Size-Fits-All” Surgery to Precision Remodeling—De-escalation Strategies and the Evolving Role of Breast Surgeons in the Post-Neoadjuvant Era

Against the backdrop of Chongqing’s mountainous skyline and flowing rivers, the 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference were successfully held in Chongqing from April 15–19, 2026.
ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

ESMO BC 2026 | A Potential New First-Line “China Regimen” for Advanced TNBC: Professor Jian Zhang Reports Phase II Study of a Novel TROP2 ADC Combined With a PD-L1/VEGF-A Bispecific Antibody

On May 8, local time, at the ESMO Breast Cancer Congress 2026 (ESMO BC 2026), Professor Jian Zhang from Fudan University Shanghai Cancer Center delivered a rapid oral presentation of efficacy and safety results from the Phase II expansion cohort evaluating the PD-L1×VEGF-A bispecific antibody Pumitamig in combination with the TROP2 antibody-drug conjugate (ADC) BNT325 (sacituzumab drozuntecan) as first-line treatment for advanced or metastatic triple-negative breast cancer (a/mTNBC) (NCT05438329).
47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

47Sino-French Breast Reconstruction Congress | Professor Yongsheng Wang: From Precision Decision-Making to Standardized Training—Advancing Individualized Axillary Management

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. During the meeting, Professor Yongsheng Wang from Shandong Cancer Hospital delivered a presentation entitled “Precision Decision-Making in Sentinel Lymph Node Biopsy”, offering an in-depth discussion on management strategies and individualized decision pathways for sentinel lymph node biopsy (SLNB).
Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

Professor Guosheng Ren & Professor Nicolas Leymarie: Rebuilding Lives, Advancing Together—Reflections and Future Perspectives on Sino-French Breast Reconstruction Collaboration | Sino-French Breast Reconstruction Congress

The 15th Sino-French Breast Reconstruction Congress and the 13th Sino-French Breast Cancer Academic Conference recently concluded successfully in Chongqing. As one of the long-standing academic meetings in the field of breast cancer, this year’s congress brought together leading Chinese and French experts in breast cancer treatment for live surgical demonstrations and in-depth discussions focused on oncoplastic breast-conserving surgery and breast reconstruction techniques.
2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

2026 HOT Conference | Professor Tengfei Chao: Precision Treatment Strategies After Progression on CDK4/6 Inhibitor Plus Endocrine Therapy

From April 16–18, 2026, the 18th Northern Breast Cancer HOT Conference was successfully held in Henan Province. The meeting focused on cutting-edge advances and clinical challenges in breast cancer diagnosis and treatment, bringing together leading Chinese experts to explore new pathways toward standardized and individualized care.
ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

ESMO BC 2026 | Academician Binghe Xu and Professor Jiayu Wang: Real-World Use of Adjuvant Abemaciclib in Chinese Patients With HR+/HER2− Early Breast Cancer

Based on the results of the monarchE trial, abemaciclib combined with endocrine therapy (ET) has become the standard adjuvant treatment for patients with high-risk HR+/HER2− early breast cancer (EBC). However, systematic data regarding its use in routine Chinese clinical practice have remained limited.